PT Jayamas Medica Industri Tbk (IDX:OMED)
Indonesia
· Delayed Price · Currency is IDR 300.00
-2.00 (-0.66%)
Apr 28, 2026, 4:12 PM WIB
IDX:OMED Income Statement
Financials in millions IDR. Fiscal year is January - December.
Millions IDR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Revenue | 2,063,817 | 1,885,822 | 1,736,990 | 1,739,054 | 2,226,573 | Upgrade
|
| Revenue Growth (YoY) | 9.44% | 8.57% | -0.12% | -21.89% | 11.63% | Upgrade
|
| Cost of Revenue | 1,346,321 | 1,261,800 | 1,184,990 | 1,176,045 | 1,322,544 | Upgrade
|
| Gross Profit | 717,496 | 624,022 | 552,000 | 563,010 | 904,030 | Upgrade
|
| Selling, General & Admin | 326,599 | 275,549 | 250,002 | 198,309 | 168,243 | Upgrade
|
| Other Operating Expenses | 1,165 | 3,016 | 1,842 | -7,542 | 2,951 | Upgrade
|
| Operating Expenses | 327,764 | 278,564 | 251,843 | 190,767 | 171,194 | Upgrade
|
| Operating Income | 389,732 | 345,458 | 300,156 | 372,243 | 732,836 | Upgrade
|
| Interest Expense | -17,320 | -19,768 | -19,581 | -20,805 | -21,840 | Upgrade
|
| Interest & Investment Income | 63,408 | 57,008 | 43,520 | 14,371 | 16,909 | Upgrade
|
| Currency Exchange Gain (Loss) | 20,147 | 11,911 | 1,654 | 6,704 | 1,445 | Upgrade
|
| Other Non Operating Income (Expenses) | -556.14 | -460.86 | -341.03 | -403.98 | -328.64 | Upgrade
|
| EBT Excluding Unusual Items | 455,410 | 394,148 | 325,409 | 372,109 | 729,020 | Upgrade
|
| Gain (Loss) on Sale of Assets | -480.18 | -121.48 | 35.59 | 0.04 | 179.92 | Upgrade
|
| Pretax Income | 454,929 | 394,026 | 325,444 | 372,109 | 729,200 | Upgrade
|
| Income Tax Expense | 85,986 | 70,074 | 64,462 | 81,602 | 158,821 | Upgrade
|
| Earnings From Continuing Operations | 368,943 | 323,952 | 260,982 | 290,507 | 570,379 | Upgrade
|
| Minority Interest in Earnings | -1,994 | -2,279 | -1,622 | -4,725 | -7,687 | Upgrade
|
| Net Income | 366,949 | 321,673 | 259,360 | 285,782 | 562,692 | Upgrade
|
| Net Income to Common | 366,949 | 321,673 | 259,360 | 285,782 | 562,692 | Upgrade
|
| Net Income Growth | 14.07% | 24.03% | -9.25% | -49.21% | -17.92% | Upgrade
|
| Shares Outstanding (Basic) | 27,041 | 27,059 | 27,059 | 27,059 | 27,059 | Upgrade
|
| Shares Outstanding (Diluted) | 27,041 | 27,059 | 27,059 | 27,059 | 27,059 | Upgrade
|
| Shares Change (YoY) | -0.07% | - | - | - | -1.44% | Upgrade
|
| EPS (Basic) | 13.57 | 11.89 | 9.59 | 10.56 | 20.80 | Upgrade
|
| EPS (Diluted) | 13.57 | 11.89 | 9.59 | 10.56 | 20.80 | Upgrade
|
| EPS Growth | 14.15% | 24.03% | -9.25% | -49.21% | -16.71% | Upgrade
|
| Free Cash Flow | 286,951 | 260,196 | -22,031 | 17,549 | 422,386 | Upgrade
|
| Free Cash Flow Per Share | 10.61 | 9.62 | -0.81 | 0.65 | 15.61 | Upgrade
|
| Dividend Per Share | - | 3.570 | 6.050 | - | 10.870 | Upgrade
|
| Dividend Growth | - | -40.99% | - | - | -36.06% | Upgrade
|
| Gross Margin | 34.77% | 33.09% | 31.78% | 32.37% | 40.60% | Upgrade
|
| Operating Margin | 18.88% | 18.32% | 17.28% | 21.40% | 32.91% | Upgrade
|
| Profit Margin | 17.78% | 17.06% | 14.93% | 16.43% | 25.27% | Upgrade
|
| Free Cash Flow Margin | 13.90% | 13.80% | -1.27% | 1.01% | 18.97% | Upgrade
|
| EBITDA | 444,100 | 388,670 | 334,660 | 392,559 | 752,142 | Upgrade
|
| EBITDA Margin | 21.52% | 20.61% | 19.27% | 22.57% | 33.78% | Upgrade
|
| D&A For EBITDA | 54,368 | 43,213 | 34,504 | 20,317 | 19,307 | Upgrade
|
| EBIT | 389,732 | 345,458 | 300,156 | 372,243 | 732,836 | Upgrade
|
| EBIT Margin | 18.88% | 18.32% | 17.28% | 21.40% | 32.91% | Upgrade
|
| Effective Tax Rate | 18.90% | 17.78% | 19.81% | 21.93% | 21.78% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.